Inside Exact Science’s Next Big Bet - One Blood Draw, More than 50 Cancers
Update: 2025-09-18
Description
“Our vision as a company is to help eradicate cancer with tests that prevent it, detect it earlier and guide treatment,” says Kevin Conroy, CEO of Exact Sciences. He joins Bloomberg Intelligence analyst Jonathan Palmer on the Vanguards of Health Care podcast to trace Exact’s journey into a cancer-diagnostics leader. From Cologuard’s initial rise to its recently launched Cologuard Plus test, the debut of Cancerguard and expansion into minimal-residual disease (MRD) testing, Conroy shares how science, technology and culture underpin the company’s next decade.
See omnystudio.com/listener for privacy information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
